Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetic lesions in preleukemia.

G Carter1, S Ridge, R A Padua

  • 1Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff, U.K.

Critical Reviews in Oncogenesis
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Change in EEG Activity is Associated with a Decrease in Tinnitus Awareness after rTMS.

Frontiers in neurology and neuroscience research·2021
Same author

Neural activity during attentional conflict predicts reduction in tinnitus perception following rTMS.

Brain stimulation·2017
Same author

Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive <i>N</i>-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of Depression.

The Journal of pharmacology and experimental therapeutics·2017
Same author

Laparoscopic Surgical Management of Juvenile Cystic Adenomyosis.

Journal of minimally invasive gynecology·2016
Same author

Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.

Leukemia·2016
Same author

The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits.

The Journal of pharmacology and experimental therapeutics·2016
Same journal

Transcription Factor and Tumorigenesis: Perspectives and Concluding Remarks.

Critical reviews in oncogenesis·2026
Same journal

Review Article: Intratumoral Immunotherapy: Old Discoveries and Recent Developments in Sarcomas.

Critical reviews in oncogenesis·2026
Same journal

Review Article: Dynamin-Related Protein 1 in Cancer Progression: Mechanisms and Implications.

Critical reviews in oncogenesis·2026
Same journal

Review Article: EZH2 in Pancreatic Cancer: Epigenetic Driver and Therapeutic Target.

Critical reviews in oncogenesis·2026
Same journal

Review Article: YY2 in Tumor Regulation: Core Mechanisms and Functional Networks.

Critical reviews in oncogenesis·2026
Same journal

Review Article: Decoding the Role of PBX3 in Cancer: Molecular Mechanisms and Therapeutic Strategies.

Critical reviews in oncogenesis·2026
See all related articles

Preleukemia involves genetic damage to stem cells, with myelodysplastic syndromes offering insights. Identifying genetic lesions like RAS and FMS mutations may predict leukemic transformation risk.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Preleukemia is a clonal stem cell disorder.
  • Leukemic transformation involves accumulating genetic lesions.
  • Myelodysplastic syndromes model human preleukemia.

Purpose of the Study:

  • To investigate genetic lesions in preleukemia.
  • To understand the role of chromosomal abnormalities in leukemic progression.
  • To identify genetic markers for predicting leukemic transformation.

Main Methods:

  • Analysis of nonrandom chromosomal abnormalities (e.g., 5q deletions, chromosome 7 deletions, trisomy 8).
  • Detection of point mutations in key genes (e.g., RAS, FMS).
  • Characterization of genetic damage in preleukemic cells.

Related Experiment Videos

Main Results:

  • Specific chromosomal changes like 5q deletions are significant.
  • Genes like FMS (encoding CSF-1 receptor) and RAS are implicated.
  • Point mutations in RAS and FMS genes are found in preleukemia patients.

Conclusions:

  • Myelodysplastic syndromes provide a model for preleukemia genetic lesions.
  • Identifying specific genetic damage is crucial for understanding preleukemia.
  • Characterizing these lesions may help identify patients at high risk for leukemia.